Bevacizumab Patent Expiration
Bevacizumab Large Molecule Patents
Given below is the list of large molecule patents protecting Bevacizumab, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Avastin | USUS10011856 | Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase | May 26, 2031 | Genentech, Inc. |
| Avastin | USUS10208355 | Method of treatment for glioblastoma by administering a VEGF antagonist | Jul 14, 2035 | Genentech, Inc. |
| Avastin | USUS10274466 | Elucidation of ion exchange chromatography input optimization | Jul 11, 2035 | Genentech, Inc. |
| Avastin | USUS10513697 | CO2 profile cultivation | Sep 17, 2032 | Genentech, Inc. |
| Avastin | USUS10704071 | Decreasing lactate level and increasing polypeptide production by down regulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase | Aug 18, 2031 | Genentech, Inc. |
| Avastin | USUS10906934 | Protein purification methods | Oct 12, 2033 | Genentech, Inc. |
| Avastin | USUS10906986 | Prevention of disulfide bond reduction during recombinant production of polypeptides | Jul 08, 2028 | Genentech, Inc. |
| Avastin | USUS7485704 | Reducing protein A leaching during protein A affinity chromatography | Mar 08, 2025 | Genentech, Inc. |
| Avastin | USUS8460895 | Method for producing recombinant proteins with a constant content of pCO2 in the medium | Aug 08, 2029 | Genentech, Inc. |
| Avastin | USUS9441035 | Cell culture media and methods of antibody production | Apr 23, 2034 | Genentech, Inc. |
| Avastin | USUS9487809 | Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase | Jan 14, 2032 | Genentech, Inc. |
| Avastin | USUS9795672 | Treatment with anti-VEGF antibodies |
May 28, 2024
(Expired) | Genentech, Inc. |
Bevacizumab's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List